OUTLOOK THERAPEUTICS, INC. Severance Costs
OUTLOOK THERAPEUTICS, INC. (OTLK) reported Severance Costs of $2.89 million for the 12-month period ending 2025-09-30, per its 10-K filed 2025-12-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2026-02-17
- OUTLOOK THERAPEUTICS, INC. severance costs for the quarter ending 2025-09-30 was $1.47M.
- OUTLOOK THERAPEUTICS, INC. severance costs for the quarter ending 2025-06-30 was $0.00.
- OUTLOOK THERAPEUTICS, INC. severance costs for the quarter ending 2025-03-31 was $0.00.
- OUTLOOK THERAPEUTICS, INC. severance costs for the quarter ending 2024-12-31 was $1.43M.
- OUTLOOK THERAPEUTICS, INC. severance costs for fiscal 2025 was $2.89M.
| Period end | Severance Costs 3 month | Severance Costs 6 month | Severance Costs 9 month | Severance Costs 12 month |
|---|---|---|---|---|
| 2025-09-30 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-19 | $1.47M derived: sum of 2 quarters · filed 2025-12-19 | $1.47M derived: sum of 3 quarters · filed 2025-12-19 | $2.89M 10-K · filed 2025-12-19 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | $0.00 derived: sum of 2 quarters · filed 2025-08-14 | $1.43M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $1.43M 10-Q · filed 2025-05-15 | ||
| 2024-12-31 | $1.43M 10-Q · filed 2026-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |